ALTSTATION.IO

Edwards Lifesciences Corporation (EW) Stock Analysis

By Nova Skye | AltStation.io | Updated October 11, 2026

Price

$83.72

Change

-0.62%

Market Cap

$48.26B

Avg Volume

3.8M

Company Overview

Edwards Lifesciences (EW) is a medical device company in the healthcare sector, headquartered in Irvine, California, and founded in 1958. They build and sell specialized technologies to treat advanced cardiovascular disease, primarily focusing on damaged heart valves. Their core product portfolio includes transcatheter aortic valve replacements under the Edwards SAPIEN brand, transcatheter mitral and tricuspid therapies under the PASCAL and EVOQUE brands, and surgical structural heart lines including INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA. They distribute these devices directly and through independent distributors to hospital networks, cardiac surgeons, and interventional cardiologists across the United States, Europe, Japan, and international markets.

Edwards holds the position of an established market leader in structural heart therapies rather than a niche player. Their primary technological edge lies in proprietary engineering like RESILIA tissue and VFit technology, which provide durability advantages and drive high clinical adoption. Competitive pressure in the medical device sector centers on competing catheter delivery systems and alternative surgical repair devices. Edwards defends its market position by leveraging its direct global sales force and maintaining comprehensive clinical coverage across aortic, mitral, and tricuspid conditions.

The company is actively executing a strategic pivot to expand beyond its traditional aortic valve core into transcatheter mitral and tricuspid interventions. Scaling therapies like EVOQUE and PASCAL represents a major milestone to capture high-unmet-need valve repair and replacement procedures worldwide. Concurrently, Edwards continues anchoring its surgical structural heart segment with specialized products like the pre-assembled KONECT RESILIA conduit for complex combined surgeries. This decisive transition into multi-valve transcatheter solutions sets up Edwards to drive long-term procedure volume growth across international cardiovascular care.

Key Financials

Market Cap

$48.26B

Revenue

$6.51B

EBITDA

$2.00B

Gross Margin

77.8%

Profit Margin

15.4%

Revenue Growth

13.6%

Total Cash

$4.25B

Total Debt

$704.40M

Free Cash Flow

$1.23B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

49.83

Forward P/E

24.74

Beta

0.86

52-Week High

$96.29

52-Week Low

$72.30

EPS

$1.68

50-Day Avg

$88.65

200-Day Avg

$85.14

Price/Book

4.55

Technical Analysis

EW trades at $83.72, placing it 54% of the way through its 52-week range of $72.30 to $96.29. The stock is 11.51% below its 52-week high and 17.86% above its 52-week low. Price is 1.69% below the 20-day moving average of $86.68, showing weak near-term positioning. Momentum is nearly flat at 0.07% over five trading days and 1.00% over 20 trading days. Near-term support is $84.24 and resistance is $90.82, with the current price already below that support level.

Recent News and Developments

Barclays upgrades EW as analysts stay bullish

Barclays upgraded Edwards Lifesciences to Strong Buy on October 7. UBS reiterated Buy on October 8, while Citigroup reiterated Buy on October 5. Source: MarketBeat

EU selects SAPIEN M3 for clinical assessment

The European Commission selected Edwards’ SAPIEN M3 as one of the first medical devices to undergo an EU-level joint clinical assessment. The review covers its use in patients with moderate-to-severe or severe mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge repair. Source: European Commission

Edwards schedules third-quarter earnings

Edwards will report results for the quarter ended September 30 after the market closes on November 4. Management will hold its earnings call at 5:00 p.m. ET that day. Source: Edwards Lifesciences

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is growing 13.6%, giving investors a clear fundamental reason to own EW. The company generates $6.51 billion in revenue and carries a $48.26 billion market capitalization. Its balance sheet is strong, with $4.25 billion in cash against $704.40 million in debt. Analysts remain bullish: 26 analysts rate EW a buy, with a consensus target of $101.96 and a high target of $110.00. Barclays upgraded EW to Strong Buy on October 7, while UBS and Citigroup reiterated Buy ratings on October 8 and October 5. The EU clinical assessment of SAPIEN M3 and the November investor events provide potential catalysts, while the gap between the $83.72 share price and the $101.96 consensus target gives buyers meaningful upside if execution stays strong.

Bear Case

EW trades at a P/E of 49.83, which leaves little room for disappointing growth or weak guidance. Revenue growth of 13.6% is solid, but investors are already paying a premium multiple for it. The stock is below its $86.68 20-day moving average and below the stated near-term support level of $84.24. It also remains 11.51% below its 52-week high, while five-day momentum is nearly flat at 0.07%. The lowest analyst target is $84.00, barely above the current price of $83.72. No competitive, margin, or macroeconomic data was provided, so those risks cannot be measured here; the clear documented risk is paying 49.83 times earnings for a stock with weak near-term price action.

What to Watch

The first event is the TCT investor session in San Diego on November 2 from 5:00 to 6:00 p.m. Pacific. Investors should listen for concrete information from physicians and management about SAPIEN M3 and the company’s outlook. Edwards reports third-quarter results after the market closes on November 4, followed by its earnings call at 5:00 p.m. ET. Revenue growth is the key fundamental marker: the current rate is 13.6%, and any change will matter because the stock trades at a P/E of 49.83. On the chart, EW needs to recover the $84.24 near-term support level and then the $86.68 moving average; $90.82 is the next listed resistance level. A move toward the $72.30 yearly low would damage the thesis, while a break above $90.82 would improve the technical setup.

Analyst Consensus

BUY

Based on 26 analyst opinions

Low Target

$84.00

Mean Target

$101.96

High Target

$110.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

16,000

Earnings & Dividends

Next Earnings

Nov 04, 2026

EPS (Trailing)

$1.68

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is EW a good stock to buy?

EW has a buy recommendation from 26 analysts and revenue growth of 13.6%. Its P/E of 49.83 makes the valuation demanding, so the takeaway is that EW offers growth but requires strong execution.

What is EW’s price target?

The consensus analyst target is $101.96, with estimates ranging from $84.00 to $110.00. The takeaway is that analysts see upside from the current $83.72 price, although the lowest target is close to the market price.

Is EW stock overvalued?

EW trades at a P/E of 49.83 while revenue is growing 13.6%. The takeaway is that the stock carries a premium valuation relative to its documented growth rate.

Does Edwards Lifesciences have a strong balance sheet?

Edwards has $4.25 billion in total cash and $704.40 million in total debt. The takeaway is that cash substantially exceeds debt.

What are the support and resistance levels for EW?

Near-term support is $84.24, and near-term resistance is $90.82. With the stock at $83.72, the takeaway is that EW is currently below the listed support level.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 11, 2026.